In the cell line experiment, they also documented that (a) by lowering CDKN2A expression they could see an increase in the effectiveness of 5-FU in the 5-FU-resistant cell line and (b) increasing the CDKN2A expression decreased the effectiveness of 5-FU in CRC cells. The gene discussed is CDKN2A; the disease is colorectal carcinoma.